BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent
Jan. 17, 2002
By
Kim Coghill
No Comments
Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent.
BioWorld